Preventing Medication Mismanagement in People Living with Dementia through Automated Medication Dispensing with Facial Recognition and Video Observation

通过面部识别和视频观察自动配药，防止痴呆症患者用药管理不善

• 批准号: 10461514
• 负责人: Charles Gellman
• 金额: $ 44.96万
• 依托单位: HIDO TECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-08-15 至 2024-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10461514
• 关键词: Accountability; Activities of Daily Living; Address; Adherence; Alzheimer' s Disease; Artificial Intelligence; Automation; Caregiver Burden; Caregivers; Caring; Cellular Phone; Clinic; Complex; Consumption; Dementia; Dementia caregivers; Development; Devices; Disease; Dose; Elderly; Emergency department visit; Ensure; Face; Family; Feedback; Goals; Health; Health Care Costs; Home; Hospitalization; Incidence; Individual; Ingestion; Intuition; Label; Lead; Legal patent; Manuals; Medical; Medication Management; Modeling; Monitor; Nursing Homes; Outcome; Patient Care; Patient Rights; Patients; Performance; Persons; Pharmaceutical Preparations; Phase; Pilot Projects; Population; Protocols documentation; Provider; Reporting; Rights; Risk Factors; Route; Sales; Schedule; Secure; Serious Adverse Event; Small Business Innovation Research Grant; Sorting - Cell Movement; Stream; System; Target Populations; Technology; Testing; Time; Update; Validation; adverse drug reaction; age related; aging in place; base; cognitive function; comorbidity; compliance behavior; cost; dashboard; design; dosage; executive function; health care service utilization; hospital readmission; improved; innovation; instrumental activity of daily living; machine vision; medication administration; medication nonadherence; new technology; novel; prevent; prototype; sensor; smartphone Application; socioeconomic disparity; software as a service; success; tool; trend; usability

Globally, over 47 million individuals are living with dementia, with new incidence of 7.7 million annually. Medication mismanagement is one of the most common and concerning risk factors in people with dementia (PwD), as it leads to undertreatment of disease, emergency department visits, hospital admissions/readmissions, and serious adverse events. In the U.S. an estimated 3 million older adults are admitted to nursing homes due to drug-related adherence problems with annual cost exceeding $14 billion. The challenge is complex medication management requires moderate executive functioning. However, as cognitive function declines, PwD can no longer perform such Instrumental Activities of Daily Living (IADLs) safely, effectively, and independently. While the goal is to keep older adults at home as long as possible, caregivers are not available 24/7 & costs of external care are often prohibitive. The HiDO platform will solve these market challenges by automating medication administration for PwD to eliminate mismanagement, decrease caregiver burden, reduce healthcare utilization and facilitate the ability for PwD to age in place. While still premarket, HiDO is being designed and validated as an automated, AI driven medication dispensing and direct observation platform to optimize adherence. The innovative device integrates medication dispensing, dose administration time, medication synchronization, and a pair of front-facing video cameras to validate the right medications, the right route, right time, right dosage to the right patient (5R’s). The cameras record every dose using facial recognition & provide real-time medication consumption recordings for medical review if needed by monitoring the time a patient interacts with the device. Through cloud connectivity, providers & caregivers have access to video observation logs, dose administration time, adherence trends, & longitudinal adherence through the platform’s dashboard. Patients & caregivers can easily setup complex medication protocols in minutes using a smartphone app. The device then alerts patients and dispenses up to 7 different types of meds simultaneously, with up to 40 doses each. The fully commercialized HiDO platform will integrate the full feature suite above. However, to demonstrate feasibility, Phase I will target an in-clinic usability study, platform enhancements & novel AI to confirm ingestion, and remote pilot study to document independent usability & adherence in PwD. An existing prototype HiDO platform, which already integrates facial recognition AI, will be leveraged as a base technology to increase likelihood of project success. First, using the existing prototype we will complete an in-clinic usability study to validate use cases and product features in the target population. The existing platform will then be enhanced with machine vision AI to confirm medication ingestion, as well as updates to address challenges found in early usability. Once the enhanced platform has been technically verified, it will be deployed in a remote field usability study with PwD and caregivers.

全球有超过4700万人患有痴呆症，每年的新发病率为770万。 药物管理不善是痴呆症患者最常见和最令人担忧的危险因素之一。 (PWD)，因为它导致疾病治疗不足、急诊科就诊、住院/再入院， 以及严重的不良事件。在美国，估计有300万老年人被送往养老院 每年花费超过140亿美元的与药物有关的坚持问题。挑战是复杂的药物治疗 管理需要适度的执行职能。然而，随着认知功能的下降，PWD不能 不再安全、有效和独立地进行这种工具性的日常生活活动(IADL)。而当 目标是让老年人尽可能长时间呆在家里，照顾者不是全天候的&外部费用 关怀往往是令人望而却步的。 HIDO平台将通过使PWD的药物管理自动化来解决这些市场挑战 消除管理不善、减轻照顾者负担、降低医疗保健利用率并促进 PWD要老化到位。虽然Hido还在上市前，但它的设计和验证是一款自动化的、人工智能驱动的产品 配药和直接观察平台，优化依从性。这款创新设备集成了 配药、给药时间、用药同步，以及一对正面视频 相机来验证正确的药物，正确的路线，正确的时间，正确的剂量给正确的患者(5R)。这个 摄像头使用面部识别记录每个剂量，并提供实时药物消耗记录 如果需要，可以通过监测患者与设备交互的时间进行医学审查。通过云连接， 提供者和护理者可以访问视频观察日志、剂量给药时间、遵守趋势和 通过平台的仪表板进行纵向坚持。患者和护理人员可以很容易地设置复杂的 使用智能手机应用程序在几分钟内完成用药方案。然后，该设备会提醒患者，并向患者分发多达7个 同时服用不同类型的药物，每种药物最多40剂。 完全商业化的HIDO平台将整合上述全功能套件。然而，为了证明 可行性，第一阶段将针对临床可用性研究、平台增强和新的人工智能以确认摄入， 和远程试点研究，以记录PWD中的独立可用性和遵守情况。现有的原型机HIDO 已经集成了面部识别AI的平台将被用作基础技术，以增加 项目成功的可能性。首先，使用现有的原型，我们将完成临床可用性研究 验证目标人群中的用例和产品功能。然后，现有平台将得到加强 使用机器视觉人工智能来确认药物摄入，以及更新以应对早期发现的挑战 可用性。一旦增强的平台经过技术验证，它将部署在远程现场可用性 与残障人士和照顾者一起学习。